Belinostat
- Generic Name
- Belinostat
- Brand Names
- Beleodaq
- Drug Type
- Small Molecule
- Chemical Formula
- C15H14N2O4S
- CAS Number
- 866323-14-0
- Unique Ingredient Identifier
- F4H96P17NZ
- Background
Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for th...
- Indication
Belinostat is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with manageable safety profile. It is a potential alternative therapy for patients who did not experience adequate response to first-line drugs for PTCL. It can be used in patients with baseline thrombocytopenia .
- Associated Conditions
- Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma
- Associated Therapies
- -
Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
- Conditions
- Interventions
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT04184869
- Locations
- 🇺🇸
John Wayne Cancer Institute @ Providence Saint John's Health Center, Santa Monica, California, United States
Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT03772925
- Locations
- 🇺🇸
Moffitt Cancer Center-International Plaza, Tampa, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
- Conditions
- Metastatic Breast CarcinomaRecurrent Breast CarcinomaRecurrent Hodgkin LymphomaRefractory Hodgkin LymphomaBreast AdenocarcinomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Nodal Marginal Zone LymphomaRecurrent Mycosis FungoidesRecurrent Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma
- Interventions
- Drug: BelinostatDrug: CarfilzomibDrug: Copanlisib HydrochlorideBiological: DaratumumabDrug: Fludeoxyglucose F-18Drug: Gemcitabine HydrochlorideOther: Laboratory Biomarker AnalysisBiological: NivolumabBiological: ObinutuzumabBiological: PembrolizumabProcedure: Positron Emission TomographyBiological: RituximabDrug: RomidepsinOther: SalineBiological: Trastuzumab
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 39
- Registration Number
- NCT03432741
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2016-08-22
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- Yale University
- Registration Number
- NCT02875002
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Massey Cancer Center, Richmond, Virginia, United States
🇺🇸Sidney Kimmel Comprehensive Cancer, Baltimore, Maryland, United States
Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 15
- Registration Number
- NCT02737046
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma
- First Posted Date
- 2016-03-08
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02701673
To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.
- Conditions
- Interventions
- First Posted Date
- 2016-02-10
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02679131
- Locations
- 🇺🇸
Innovative Clinical Research Institute, Whittier, California, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-08-25
- Last Posted Date
- 2016-01-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02532192
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
- Conditions
- Acute Myeloid LeukemiaPreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Myeloid LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRefractory Chronic Myelogenous Leukemia, BCR-ABL1 PositiveSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid LeukemiaMyelodysplastic SyndromeUntreated Adult Acute Myeloid LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Interventions
- First Posted Date
- 2015-03-06
- Last Posted Date
- 2018-05-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT02381548
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
- Conditions
- Interventions
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT02142530
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth-Israel Deaconess Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.